Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer
Autore:
Lim, SC; Park, KO; Kim, YC; Na, KJ; Song, HC; Bom, HS;
Indirizzi:
Chonnam Univ Hosp, Dept Internal Med, Kwangju 501757, South Korea Chonnam Univ Hosp Kwangju South Korea 501757 Kwangju 501757, South Korea Chonnam Univ Hosp, Dept Thorac & Cardiovasc Surg, Kwangju 501757, South Korea Chonnam Univ Hosp Kwangju South Korea 501757 Kwangju 501757, South Korea Chonnam Univ Hosp, Dept Nucl Med, Kwangju 501757, South Korea Chonnam UnivHosp Kwangju South Korea 501757 Kwangju 501757, South Korea
Titolo Testata:
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
fascicolo: 4, volume: 15, anno: 2000,
pagine: 381 - 386
SICI:
1084-9785(200008)15:4<381:COTSSN>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; PROGNOSTIC VALUE; TUMOR-MARKERS; TECHNETIUM-99M-SESTAMIBI; CARCINOMA; ANTIGEN; KINASE; SPECT;
Keywords:
Tc-99m sestamibi; dipyridamole; small cell lung cancer; neuron specific enolase; lactate dehydrogenase;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Lim, SC Chonnam Univ Hosp, Dept Internal Med, 8 Hakdong, Kwangju 501757, South Korea Chonnam Univ Hosp 8 Hakdong Kwangju South Korea 501757 outh Korea
Citazione:
S.C. Lim et al., "Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer", CANC BIO R, 15(4), 2000, pp. 381-386

Abstract

Neuron-specific enolase (NSE) and lactate dehydrogenase (LDH) are tumor markers of small cell lung cancer (SCLC) which were reported to predict outcome of patients with SCLC. We previously reported that dipyridamole-modulated Tc-99m sestamibi (dipyridamole-MIBI) single photon emission computed tomography (SPECT) could predict the response to chemotherapy in SCLC patients. The purpose of this study was to compare dipyridamole-MIBI and pretreatment serum levels of NSE and LDH for the prediction of response to chemotherapy in SCLC. Twenty-eight SCLC patients underwent dipyridamole-MIBI SPECT 3 to 7 days before starting chemotherapy (80 mg/m(2) etoposide and 80 mg/m2 cisplatin every 3 or 4 weeks for at lease two cycles). Serum levels of NSE and LDH were also measured at the same day of the imaging. Tomographic imagesbefore and after 0.84 mg/kg dipyridamole infusion were acquired 1 hour after injection of 370 (10 mCi) and 1,110 (30 mCi) MBq MIBI: respectively. Theresponse to chemotherapy was grouped as specified as complete (CR), partial response (PR), no change (NC), and progressive disease (PD), according tothe change in tumor size on chest roentgenography and CI: Patients showingCR and PR were classified as responders, and those who showed NC and PD were considered nonresponders. Among the 28 patients, 15 were responders (2 CR 13 PR) and 13 were nonresponders (II NC, 2 PD). The change of tumor-to-normal lung ratio (T:NL) after infusion of dipyridamole was significantly higher in responders as compared with nonresponders (0.38+/-0.64 vs. -0.38+/-0.50, respectively p=0.002). However pretreatment serum NSE and LDH levels did not correlate with the response to chemotherapy. Increase of T:NL after dipyridamole infusion was a strong negative predictor of chemotherapeutic response in SCLC patients while NSE and LDH could not predict it.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 12:22:43